ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Grant

Date/time Interval

  • December 13, 2017 - December 12, 2022
  • Total Award Amount

  • 54500.00
  • Direct Costs

  • 40073.00
  • Sponsor Award Id

  • Contributor

  • Alva, Elizabeth   Investigator  
  • Aye, Jamie   Investigator  
  • Friedman M.D., Gregory   Principal Investigator  
  • Galtarossa Xavier, Ana   Investigator  
  • Kutny M.D., Matthew   Investigator  
  • Liang, Wayne   Investigator  
  • Whelan M.D., Kimberly   Investigator